Franck Morschhauser, Christian Recher, Noël Milpied, Remy Gressin, Gilles Salles, et al.. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma..
Annals of Oncology, Elsevier, 2012, 23 (10), pp.2687-95.
⟨10.1093/annonc/mds202⟩.
⟨inserm-00862711⟩